Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders

Ronan, Patrick J.; Flynn, Sarah; Beresford, Thomas P.

doi:10.1016/bs.pmbts.2019.06.008

Cited by 1 publication

(1 citation statement)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most commonly studied transcription factors are nuclear factors of activated T-cells (NFAT 1-5), nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), the forkhead transcription factors, and transcription factor EB. These factors drive the release of proinflammatory cytokines as interleukins, interferons, CD40 ligand, tumor necrosis factors, and T-cell receptor (TCR) signaling involved in the activation of T lymphocytes responding to foreign antigens, autoantigens, or alloantigens [13]. Interleukins/cytokines further activate downstream signaling via phosphatidyl-inositol-3 kinase, and the mammalian target of rapamycin, which all regulate the activation, proliferation, and differentiation of T cells (Figure 1) [14].…”

Section: Calcineurin As a Molecular Drug Targetmentioning

confidence: 99%

Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis

Kale,

Shelke,

Lei

et al. 2023

Cells

View full text Add to dashboard Cite

Calcineurin inhibitors (CNI) can suppress allo- and autoimmunity by suppressing T cell function but also have anti-proteinuric effects by stabilizing the cellular components of the kidney’s filtration barrier. Therefore, CNI are used in autoimmune kidney diseases with proteinuria. However, the traditional CNI, cyclosporine A and tacrolimus, have a narrow therapeutic range, need monitoring of drug levels, and their use is associated with nephrotoxicity and metabolic alterations. Voclosporin (VOC), a novel CNI, no longer requires drug level monitoring and seems to lack these adverse effects, although hypertension and drug–drug interactions still occur. VOC demonstrated efficacy superior to standard-of-care in controlling active lupus nephritis in the phase 2 AURA-LV and the phase 3 AURORA-1 trials and was approved for the treatment of active lupus nephritis. However, how to implement VOC into the current and changing treatment landscape of lupus nephritis is still debated. Here, we review the unique chemistry, pharmacology, and toxicity profile of VOC, summarize the efficacy and safety data from the AURA-LV and AURORA-1 trials, and discuss the following four possible options to implement VOC into the management of lupus nephritis, namely regarding B cell-targeting therapy with belimumab (BEL). These include: 1. patient stratification to either VOC or BEL, 2. VOC/BEL combination therapy, 3. VOC-BEL sequential therapy, or 4. alternative options for the rapid antiproteinuric effect of VOC.

show abstract

Section: Calcineurin As a Molecular Drug Targetmentioning

confidence: 99%